Concepedia

Akihiko Koyama

AK

16

Publications

2.6K

Citations

15

H-Index

1999

Active since

Affiliations

Eisai (United States)(Current)

The University of Tokyo

University of California, San Francisco

Washington University in St. Louis

Eisai (Japan)

Akihiko Koyama is an author at Eisai (United States) specializing in neurodegenerative diseases, cell biology, and medicine.

ORCID

Top concepts

Publications per year

1999–2023

16

Publications

16

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

Chad J. Swanson, Yong Zhang, Shobha Dhadda et al. · Alzheimer s Research & Therapy · 2021 · 757 citations · Full text

Constitutive Phosphorylation of the Parkinson's Disease Associated α-Synuclein

Masayasu Okochi, Jochen Walter, Akihiko Koyama et al. · Journal of Biological Chemistry · 2000 · 507 citations · Full text

Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study

Eric McDade, Jeffrey L. Cummings, Shobha Dhadda et al. · Alzheimer s Research & Therapy · 2022 · 260 citations · Full text

CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease

Kanta Horie, Gemma Salvadó, Nicolas R. Barthélemy et al. · Nature Medicine · 2023 · 232 citations · Full text

Human P301L-Mutant Tau Expression in Mouse Entorhinal-Hippocampal Network Causes Tau Aggregation and Presynaptic Pathology but No Cognitive Deficits

Julie A. Harris, Akihiko Koyama, Sumihiro Maeda et al. · PLoS ONE · 2012 · 146 citations · Full text

, , +22

Rows per page

1–5 of 16